Validation of the aMAP score to predict hepatocellular carcinoma development in a cohort of alcohol‐related cirrhosis patients
Liver Cancer International · 2022-06 · 3 (2) · 99-104
DOI: 10.1002/lci2.47 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver Cancer International, online erschienen am 12.03.2022. Verfasst von Ken Liu und 8 weiteren Autor:innen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute on Alcohol Abuse and Alcoholism.
Abstract (Originalsprache)
Background and Aims The aMAP score was recently devised to predict hepatocellular carcinoma (HCC) development. However, its performance was not tested in alcohol‐related cirrhosis (ALC). We aimed to validate the aMAP score in a cohort of ALC patients.
Method
Study participants with ALC from a prior genome‐wide association study were included. All participants had a history of high alcohol consumption. Cirrhosis was defined clinically, using fibroscan and/or histology. Patients were followed until the last liver imaging, HCC, liver transplantation (LT) or death with the latter two adjusted as competing risks.
Results
A total of 269 ALC patients were included: male (72.5%), Caucasian (98.9%), median age 56 years, and median Child‐Pugh score 7. The median aMAP score was 60: 12.3% low‐risk, 35.3% medium‐risk and 52.4% high‐risk. After a median follow‐up of 41 months, 14 patients developed HCC, 27 received LT and 104 died. The aMAP score predicted HCC development (hazard ratio 1.12 per point increase, P < .001) with good separation of cumulative incidence function between risk groups. The area under the time‐dependent receiver operating characteristics curve for predicting HCC development was 0.83 at 1 year and 0.82 at 5 years which was similar to ADRESS‐HCC and Veterans Affairs Healthcare System scores respectively.
Conclusions
We validated the excellent performance of the aMAP score in ALC and affirm its applicability across wider aetiologies.
Förderung
- National Institute on Alcohol Abuse and Alcoholism
Zitieren
APA
Liu, K., Yip, T. C. F., Masson, S., Fateen, W., Schwantes‐An, T., McCaughan, G. W., Morgan, T. R., Aithal, G. P., & Seth, D. (2022). Validation of the aMAP score to predict hepatocellular carcinoma development in a cohort of alcohol‐related cirrhosis patients. Liver Cancer International, 3(2), 99-104. https://doi.org/10.1002/lci2.47
Vancouver
Liu K, Yip TCF, Masson S, Fateen W, Schwantes‐An T, McCaughan GW, et al. Validation of the aMAP score to predict hepatocellular carcinoma development in a cohort of alcohol‐related cirrhosis patients. Liver Cancer International. 2022;3(2):99-104. doi:10.1002/lci2.47
BibTeX
@article{Liu2022,
author = {Liu, Ken and Yip, Terry C. F. and Masson, Steven and Fateen, Waleed and Schwantes‐An, Tae‐Hwi and McCaughan, Geoffrey W. and Morgan, Timothy R. and Aithal, Guruprasad P. and Seth, Devanshi},
title = {Validation of the aMAP score to predict hepatocellular carcinoma development in a cohort of alcohol‐related cirrhosis patients},
journal = {Liver Cancer International},
year = {2022},
volume = {3},
number = {2},
pages = {99--104},
doi = {10.1002/lci2.47}
}
EUVIMED